Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Moxifloxacin hydrochloride
Drug ID BADD_D01502
Description Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
Indications and Usage For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
Marketing Status Prescription; Discontinued
ATC Code J01MA14; S01AE07
DrugBank ID DB00218
KEGG ID D00874
MeSH ID D000077266
PubChem ID 101526
TTD Drug ID D0ZV0Z
NDC Product Code 60429-893; 58032-0131; 65862-603; 51991-943; 0065-0006; 50268-576; 49574-522; 72789-037; 48943-0025; 72789-038; 51927-0167; 0832-1410; 48943-0024; 68084-722; 13668-201; 57237-156; 66298-8507; 0781-7135; 29967-0005; 0065-4013; 63323-850; 0078-0939; 50370-0001; 0093-7387; 67457-323; 67296-1616; 50090-4100; 65862-627; 50090-4058; 55111-064; 49587-106; 40032-034; 51927-4833; 51927-0089
Synonyms Moxifloxacin | 1-Cyclopropyl--7-(2,8-diazabicyclo(4.3.0)non-8-yl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid | Octegra | Proflox | Moxifloxacin Hydrochloride | Avelox | Avalox | Izilox | Actira | BAY 12-8039 | BAY 12 8039 | BAY-12-8039 | BAY 128039 | BAY-128039 | BAY128039
Chemical Information
Molecular Formula C21H25ClFN3O4
CAS Registry Number 186826-86-8
SMILES COC1=C2C(=CC(=C1N3CC4CCCNC4C3)F)C(=O)C(=CN2C5CC5)C(=O)O.Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Breast disorder21.05.04.004--Not Available
Cardiac disorder02.01.01.003--Not Available
Connective tissue disorder15.06.01.006--Not Available
Infestation23.09.05.001; 11.09.01.001--Not Available
Inflammation08.01.05.007--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Oral fungal infection07.05.07.009; 11.03.05.010--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Ill-defined disorder08.01.03.049--Not Available
Inner ear disorder04.04.02.002--Not Available
Sensation of foreign body08.01.09.002--Not Available
Blood disorder01.05.01.004--Not Available
Psychotic disorder19.03.01.002--
Hepatobiliary disease09.01.08.003--Not Available
Hyperlipidaemia14.08.03.001--
Urine analysis abnormal13.13.02.008--Not Available
Renal impairment20.01.03.010--Not Available
Cystitis noninfective20.03.02.001--
Self injurious behaviour19.12.01.005--Not Available
Infusion site extravasation12.07.05.008; 08.02.05.007--
Vulvovaginal mycotic infection11.03.05.004; 21.14.02.004--Not Available
Ventricular tachyarrhythmia02.03.04.012--Not Available
Liver injury12.01.02.003; 09.01.07.022--Not Available
Adverse reaction08.06.01.018--Not Available
Acute kidney injury20.01.03.016--
Acute yellow liver atrophy09.01.07.026--Not Available
Candida infection11.03.03.021--
Multiple organ dysfunction syndrome08.01.03.057--
The 14th Page    First    Pre   14 15    Next   Last    Total 15 Pages